Leerink Partnrs Has Weak Outlook for OmniAb FY2025 Earnings

OmniAb, Inc. (NASDAQ:OABI) – Investment analysts at Leerink Partnrs reduced their FY2025 earnings estimates for shares of OmniAb in a note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings per share of ($0.64) for the year, down from their previous forecast of ($0.63). The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. Leerink Partnrs also issued estimates for OmniAb’s Q4 2025 earnings at ($0.15) EPS and FY2026 earnings at ($0.61) EPS.

Several other research firms have also recently weighed in on OABI. Benchmark cut their target price on shares of OmniAb from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of OmniAb in a research note on Wednesday.

OmniAb Price Performance

Shares of OABI stock opened at $2.53 on Friday. The company has a market capitalization of $357.28 million, a price-to-earnings ratio of -4.08 and a beta of -0.14. OmniAb has a one year low of $2.23 and a one year high of $5.63. The company’s fifty day moving average price is $3.34 and its 200-day moving average price is $3.77.

OmniAb (NASDAQ:OABI) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.01. The firm had revenue of $10.80 million for the quarter, compared to the consensus estimate of $10.13 million. OmniAb had a negative net margin of 308.78% and a negative return on equity of 20.97%. During the same period last year, the firm earned ($0.14) EPS.

Insider Buying and Selling

In other OmniAb news, Director John L. Higgins purchased 125,750 shares of OmniAb stock in a transaction dated Thursday, March 20th. The stock was acquired at an average price of $2.35 per share, for a total transaction of $295,512.50. Following the acquisition, the director now owns 2,762,887 shares in the company, valued at $6,492,784.45. This trade represents a 4.77 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Charles S. Berkman sold 8,215 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $3.68, for a total transaction of $30,231.20. Following the completion of the sale, the insider now owns 364,131 shares of the company’s stock, valued at approximately $1,340,002.08. This represents a 2.21 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 112,260 shares of company stock valued at $376,601. Company insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On OmniAb

Large investors have recently modified their holdings of the business. Invesco Ltd. raised its stake in shares of OmniAb by 3.3% during the 4th quarter. Invesco Ltd. now owns 93,653 shares of the company’s stock worth $332,000 after acquiring an additional 2,997 shares in the last quarter. Connors Investor Services Inc. raised its stake in shares of OmniAb by 18.4% during the 4th quarter. Connors Investor Services Inc. now owns 29,611 shares of the company’s stock worth $105,000 after acquiring an additional 4,611 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of OmniAb by 16.5% during the 4th quarter. SG Americas Securities LLC now owns 40,609 shares of the company’s stock worth $144,000 after acquiring an additional 5,751 shares in the last quarter. Sherbrooke Park Advisers LLC raised its stake in shares of OmniAb by 53.5% during the 4th quarter. Sherbrooke Park Advisers LLC now owns 17,226 shares of the company’s stock worth $61,000 after acquiring an additional 6,001 shares in the last quarter. Finally, Isthmus Partners LLC raised its stake in shares of OmniAb by 1.6% during the 4th quarter. Isthmus Partners LLC now owns 453,135 shares of the company’s stock worth $1,604,000 after acquiring an additional 7,001 shares in the last quarter. Institutional investors own 72.08% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.